Cargando…

The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A

Neurodegenerative diseases are a group of disorders characterized by progressive loss of certain populations of neurons, which eventually lead to dysfunction. These diseases include Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). Immune pathway dysregulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Jiajia, Huang, Yan, Bao, Ting, Liu, Chengcheng, Liu, Xi, Chen, Xueping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034482/
https://www.ncbi.nlm.nih.gov/pubmed/35459141
http://dx.doi.org/10.1186/s12974-022-02446-6
_version_ 1784693119826001920
author Fu, Jiajia
Huang, Yan
Bao, Ting
Liu, Chengcheng
Liu, Xi
Chen, Xueping
author_facet Fu, Jiajia
Huang, Yan
Bao, Ting
Liu, Chengcheng
Liu, Xi
Chen, Xueping
author_sort Fu, Jiajia
collection PubMed
description Neurodegenerative diseases are a group of disorders characterized by progressive loss of certain populations of neurons, which eventually lead to dysfunction. These diseases include Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). Immune pathway dysregulation is one of the common features of neurodegeneration. Recently, there is growing interest in the specific role of T helper Th 17 cells and Interleukin-17A (IL-17A), the most important cytokine of Th 17 cells, in the pathogenesis of the central nervous system (CNS) of neurodegenerative diseases. In the present study, we summarized current knowledge about the function of Th17/IL-17A, the physiology of Th17/IL-17A in diseases, and the contribution of Th17/IL-17A in AD, PD, and ALS. We also update the findings on IL-17A-targeting drugs as potentially immunomodulatory therapeutic agents for neurodegenerative diseases. Although the specific mechanism of Th17/IL-17A in this group of diseases is still controversial, uncovering the molecular pathways of Th17/IL-17A in neurodegeneration allows the identification of suitable targets to modulate these cellular processes. Therapeutics targeting IL-17A might represent potentially novel anti-neurodegeneration drugs.
format Online
Article
Text
id pubmed-9034482
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90344822022-04-24 The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A Fu, Jiajia Huang, Yan Bao, Ting Liu, Chengcheng Liu, Xi Chen, Xueping J Neuroinflammation Review Neurodegenerative diseases are a group of disorders characterized by progressive loss of certain populations of neurons, which eventually lead to dysfunction. These diseases include Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). Immune pathway dysregulation is one of the common features of neurodegeneration. Recently, there is growing interest in the specific role of T helper Th 17 cells and Interleukin-17A (IL-17A), the most important cytokine of Th 17 cells, in the pathogenesis of the central nervous system (CNS) of neurodegenerative diseases. In the present study, we summarized current knowledge about the function of Th17/IL-17A, the physiology of Th17/IL-17A in diseases, and the contribution of Th17/IL-17A in AD, PD, and ALS. We also update the findings on IL-17A-targeting drugs as potentially immunomodulatory therapeutic agents for neurodegenerative diseases. Although the specific mechanism of Th17/IL-17A in this group of diseases is still controversial, uncovering the molecular pathways of Th17/IL-17A in neurodegeneration allows the identification of suitable targets to modulate these cellular processes. Therapeutics targeting IL-17A might represent potentially novel anti-neurodegeneration drugs. BioMed Central 2022-04-22 /pmc/articles/PMC9034482/ /pubmed/35459141 http://dx.doi.org/10.1186/s12974-022-02446-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Fu, Jiajia
Huang, Yan
Bao, Ting
Liu, Chengcheng
Liu, Xi
Chen, Xueping
The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A
title The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A
title_full The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A
title_fullStr The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A
title_full_unstemmed The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A
title_short The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A
title_sort role of th17 cells/il-17a in ad, pd, als and the strategic therapy targeting on il-17a
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034482/
https://www.ncbi.nlm.nih.gov/pubmed/35459141
http://dx.doi.org/10.1186/s12974-022-02446-6
work_keys_str_mv AT fujiajia theroleofth17cellsil17ainadpdalsandthestrategictherapytargetingonil17a
AT huangyan theroleofth17cellsil17ainadpdalsandthestrategictherapytargetingonil17a
AT baoting theroleofth17cellsil17ainadpdalsandthestrategictherapytargetingonil17a
AT liuchengcheng theroleofth17cellsil17ainadpdalsandthestrategictherapytargetingonil17a
AT liuxi theroleofth17cellsil17ainadpdalsandthestrategictherapytargetingonil17a
AT chenxueping theroleofth17cellsil17ainadpdalsandthestrategictherapytargetingonil17a
AT fujiajia roleofth17cellsil17ainadpdalsandthestrategictherapytargetingonil17a
AT huangyan roleofth17cellsil17ainadpdalsandthestrategictherapytargetingonil17a
AT baoting roleofth17cellsil17ainadpdalsandthestrategictherapytargetingonil17a
AT liuchengcheng roleofth17cellsil17ainadpdalsandthestrategictherapytargetingonil17a
AT liuxi roleofth17cellsil17ainadpdalsandthestrategictherapytargetingonil17a
AT chenxueping roleofth17cellsil17ainadpdalsandthestrategictherapytargetingonil17a